Recent Quarter Total Invested
$247,853
-$94,147.00
Recent Quarter Institutional Ownership Percentage
14.16%
$0.32
Total Invested of Last Quarter
$342,000
Ownership Percentage of Last Quarter
13.84%
Protagenic Therapeutics, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 02/10/2023 | 236,309 | $94,523 | -6.53% | 5.47% |
| GEODE CAPITAL MANAGEMENT, LLC | 02/13/2023 | 103,595 | $43,000 | -0.27% | 2.40% |
| FNY INVESTMENT ADVISERS, LLC | 01/10/2023 | 75,000 | $31,000 | 0.00% | 1.74% |
| STATE STREET CORP | 05/15/2023 | 55,246 | $23,093 | 0.00% | 1.28% |
| CITADEL ADVISORS LLC | 02/14/2023 | 23,482 | $9,815 | 45.58% | 0.54% |
| NORTHERN TRUST CORP | 02/13/2023 | 22,485 | $8,994 | 0.00% | 0.52% |
| WARBERG ASSET MANAGEMENT LLC | 02/13/2023 | 20,000 | $8,000 | 100.00% | 0.46% |
| UBS GROUP AG | 02/08/2023 | 17,153 | $6,861 | 164.83% | 0.40% |
| CONCORDE ASSET MANAGEMENT, LLC | 02/02/2023 | 16,718 | $6,687 | 0.00% | 0.39% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 02/14/2023 | 13,977 | $5,842 | 100.00% | 0.32% |
| ADVISOR GROUP HOLDINGS, INC. | 02/10/2023 | 11,055 | $4,000 | 0.00% | 0.26% |
| VIRTU FINANCIAL LLC | 02/15/2023 | 10,110 | $4,000 | -4.44% | 0.23% |
| TOWER RESEARCH CAPITAL LLC (TRC) | 02/10/2023 | 6,206 | $2,000 | -4.92% | 0.14% |
| WELLS FARGO & COMPANY/MN | 02/13/2023 | 90 | $36 | 100.00% | 0.00% |
| BANK OF AMERICA CORP /DE/ | 02/10/2023 | 4 | $2 | 100.00% | 0.00% |
| CWM, LLC | 02/01/2023 | 3 | $0 | 0.00% | 0.00% |
| MORGAN STANLEY | 02/14/2023 | 1 | $0 | -50.00% | 0.00% |
| HARBOR INVESTMENT ADVISORY, LLC | 01/24/2023 | 1 | $0 | 0.00% | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 01/30/2023 | 0 | $0 | 0.00% | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC | 02/13/2023 | 0 | $0 | -100.00% | 0.00% |
Protagenic Therapeutics, Inc.institutional Ownership - Frequently Asked Questions
-
What percentage of Protagenic Therapeutics, Inc. stock is owned by institutional investors?
14.16% of Protagenic Therapeutics, Inc. stock is owned by institutional investors.